iBio is developing proprietary products for the treatment of a range of fibrotic diseases, including idiopathic pulmonary fibrosis, systemic sclerosis and scleroderma. IBIO-CFB03, produced using the company’s iBioLaunch™ gene expression platform, is the first product candidate from this program designated for IND development. The company also offers proprietary products and product licenses to others, based on its proprietary iBioLaunch™ gene expression and iBioModulator™ thermostable immunomodulator protein platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. For more information, visit the company’s website at www.ibioinc.com